Roche has agreed to sell three of its products to the Iceland-based generics company Actavis Group. The deal covers the cardiovascular drugs Bezalip and Rapilysin and dermatology med Neotigason, with combined 2006 sales of $117.3 million. Roche will continue to sell the remedies in Latin America under license from Actavis. The deal is part of Roche's strategy of retrenching to its core products. It's expected to close around year's end.
- check out this release for more